Foundation models that simulate human behavior -- 'synthetic users' for product and marketing research.
Simile builds foundation models that simulate human behavior -- 'synthetic users' businesses use for product, marketing, and policy research. Founded in 2026 by Stanford's Joon Sung Park (of the 'Smallville' generative-agents research) with Michael Bernstein, Percy Liang, and Lainie Yallen, it launched in February 2026 with a $100M Series A led by Index Ventures. Five months later it raised a $200M Series B at a $2B valuation led by Greenoaks (with Index, Bain Capital Ventures, Hanabi, A*, Factory, Definition, and CVS Health Ventures). Revenue has grown roughly 5x since launch; customers include CVS Health, Wealthfront, Deloitte, and Gallup.
AI📍 San Francisco, CAFounded 2026
Current Valuation
$2.0B
as of 2026-Q3
UNICORN
QL Price
$2.0B
0% vs last round
QuantLogix's current estimate for Simile, published 2026-09-20 — in line with the last disclosed round of $2.0B (2026-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$2.0B
2026-Q3
weight 1
How this price has held up
No round has priced for Simile since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-20 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Simile, 2026-09-20 (6a9a397df87ee766).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Simile going public?
No. Simile is private and has not filed to go public. There is no S-1 on file.
What is Simile's valuation in 2026?
Simile is valued at $2.0B as of 2026-Q3, set by its Series B ($200M, Jul 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Simile filed an S-1?
No public S-1 is on file for Simile.
Who are Simile's investors?
Simile's investors include Greenoaks, Index Ventures, Bain Capital Ventures, Hanabi, A*, Factory and 2 more.
Can you buy Simile stock?
No. Simile is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Simile on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Joon Sung Park
Founded
2026
HQ
San Francisco, CA
Employees
~50
Total Raised
$300M
Growth
Revenue up ~5x since Feb 2026 launch; customers incl. CVS Health, Wealthfront, Deloitte, Gallup
Last Round
Series B — $200M (Jul 2026) · Lead: Greenoaks
IPO Status
private
Fundraising Status
Series B · $200M · 2 mo ago
privateTotal raised $300M1 disclosed rounds
Series B Impact
Round Size
$200M
Primary financing announced
Post-Money Valuation
$2.0B
Company-announced mark
Round / Post-Money
10.0%
New capital ÷ post-money
Disclosed Funding
$300M
Cumulative disclosed rounds
Step-up compares disclosed post-money valuations. Round / post-money is a financing-size ratio, not an ownership or dilution estimate.
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series B
$200M
Jul 2026
Greenoaks
$2.0B
Vertical Intelligence — AI / ML
No verified Hugging Face organization found for Simile — no attributable open-model footprint. Closed-weights labs are common; this is a distribution signal, not a capability judgment.
Checked huggingface.co as of 2026-09-18. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+60% vs 2026-08
Open roles
16
via ashby
Product-build share
44%
engineering, research, product, design
Trajectory
expanding
balanced build + GTM — 44% builders vs 56% go-to-market/G&A — scaling both sides.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Product Engineer - Member of Technical StaffResearch - Member of Technical StaffEvaluations Engineering - Member of Technical StaffSecurity Engineer - Member of Technical StaffInfrastructure Engineer - Member of Technical StaffBrand Designer
Counted from Simile's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Greenoaks · Index Ventures · Bain Capital Ventures · Hanabi · A* · Factory · Definition · CVS Health Ventures
Products
Agentic twin simulations of real consumers
Synthetic-user behavioral simulation platform
Competitors
Synthetic Users · Aaru · Roundtable
AISynthetic UsersBehavioral SimulationFoundation ModelsMarket Research
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q3. Refreshed quarterly.